YILING PHARMACEUTICAL(SZ:002603) Huaan Securities·2026-01-30 00:30Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company is expected to achieve a net profit attributable to shareholders of 1.2 to 1.3 billion yuan in 2025, marking a turnaround from losses, with a similar range for the net profit excluding non-recurring items [3] - The company has made significant improvements in profitability, with a notable focus on cost management and efficiency enhancement [3] - The company has a diverse portfolio of proprietary traditional Chinese medicine products, with 17 patents covering 8 major clinical disease systems [4] - The company is progressing well in its research and development of traditional Chinese medicine, with several new drug applications accepted for review [4] - The company has successfully launched a new chemical drug, the Anilofin injection, which provides a new treatment option for postoperative pain [5] Financial Performance Summary - The company forecasts revenues of 8.03 billion yuan in 2025, 9.11 billion yuan in 2026, and 10.5 billion yuan in 2027, representing year-on-year growth rates of 23.3%, 13.4%, and 15.3% respectively [6] - The net profit attributable to the parent company is projected to be 1.228 billion yuan in 2025, 1.428 billion yuan in 2026, and 1.65 billion yuan in 2027, with a year-on-year growth of 16.2% and 15.5% [6] - The gross margin is expected to improve from 50.2% in 2024 to 52.9% in 2027 [6] - The company’s return on equity (ROE) is projected to recover from -7.1% in 2024 to 11.4% in 2027 [6] Research and Development Progress - The company has a clear development strategy with multiple innovative drug candidates in clinical stages, including treatments for acute myeloid leukemia and ischemic stroke [5] - The company is focusing on expanding its product offerings in respiratory, endocrine, digestive, gynecological, and pediatric diseases [4]